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New Findings
 What is the central question of this study?
Will a chronic reduction of neuronal excitability within the paraventricular nucleus of the
hypothalamus reduce arterial blood pressure and sympathetic activity in the long term in an
animal model of neurogenic hypertension?
 What is the main finding and its importance?
We show, for the first time, that overexpression of an inwardly rectifying potassium channel
in the paraventricular nucleus provided a long-term (>60 days) antihypertensive response
in conscious spontaneously hypertensive rats that was associated with a reduction in
neurohumorally mediated vasoconstriction, enhanced baroreflex sensitivity and reduced
peripheral chemosensitivity; no such response was observed in normotensive rats. Our results
support the paraventricular nucleus as a therapeutic target for the chronic control of blood
pressure in neurogenic hypertension.
Changes in the sympathetic nervous system are responsible for the initiation, development
and maintenance of hypertension. An important central sympathoexcitatory region is the
paraventricular nucleus (PVN) of the hypothalamus, which may become more active in
hypertensive conditions, as shown in acute studies previously. Our objective was to depress PVN
neuronal activity chronically by the overexpression of an inwardly rectifying potassium channel
(hKir2.1), while evaluating the consequences on blood pressure (BP) and its reflex regulation.
In spontaneously hypertensive rats (SHRs) and Wistar rats (WKY) lentiviral vectors (LVV-
hKir2.1; LV-TREtight-Kir-cIRES-GFP5 4 × 109 IU and LV-Syn-Eff-G4BS-Syn-Tetoff 6.2 × 109
IU in a ratio 1:4) were stereotaxically microinjected bilaterally into the PVN. Sham-treated SHRs
and WKY received bilateral PVN microinjections of LVV-eGFP (LV-Syn-Eff-G4BS-Syn-Tetoff
6.2 × 109 IU and LV-TREtight-GFP 5.7 × 109 IU in a ratio 1:4). Blood pressure was monitored
continuously by radio-telemetry and evaluated over 75 days. Baroreflex gain was evaluated
using phenylephrine (25 μg ml−1, i.v.), whereas lobeline (25 μg ml−1, i.v.) was used to stimulate
peripheral chemoreceptors. In SHRs but not normotensive WKY rats, LVV-hKir2.1 expression
in the PVN produced time-dependent and significant decreases in systolic (from 158 ± 3 to
132 ± 6 mmHg; P < 0.05) and diastolic BP (from 135 ± 4 to 113 ± 5 mmHg; P < 0.05). The
systolic BP low-frequency band was reduced (from 0.79 ± 0.13 to 0.42 ± 0.09 mmHg2; P < 0.05),
suggesting reduced sympathetic vasomotor tone. Baroreflex gain was increased and peripheral
chemoreflex depressed after PVN microinjection of LVV-hKir2.1. We conclude that the PVN
plays a major role in long-term control of BP and sympathetic nervous system activity in SHRs.
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This is associated with reductions in both peripheral chemosensitivity and respiratory-induced
sympathetic modulation and an improvement in baroreflex sensitivity. Our results support the
PVN as a powerful site to control BP in neurogenic hypertension.
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Introduction
Essential arterial hypertension has now reached pandemic
proportions, with an estimated one billion sufferers
worldwide. The pathogenesis of essential arterial
hypertension is multifactorial and not completely
understood, but there is clear evidence that chronic
elevation of sympathetic nervous system activity is a major
contributor to the onset, development and maintenance
of the hypertensive state (Grassi, 2004b; Guyenet, 2006;
Fisher & Paton, 2012). In fact, the increase of sympathetic
outflow to the heart results in increased cardiac output and
neurally mediated vasoconstriction, leading to elevated
blood pressure values (Schlaich et al. 2012). In ‘white
coat’ and borderline hypertensive patients, sympathetic
nerve activity to the arterioles supplying skeletal muscle is
raised in comparison to healthy individuals (Grassi, 2004a;
Smith et al. 2004). Excessive sympathetic activity may
contribute to hypertrophy of vascular smooth muscle and
cardiac muscle, brain hypoperfusion and inflammation,
and becomes a major target to control in neurogenic
hypertension (Zubcevic et al. 2011).
The evaluation of sympathetic activity can be achieved
indirectly by applying mathematical tools such fast Fourier
transform to blood pressure signals (Task Force of the
European Society of Cardiology and the North American
Society of Pacing and Electrophysiology, 1996). A power
spectrum is generated, where the low frequencies (LFs)
represent predominantly sympathetic activity and high
frequencies (HFs) are related to parasympathetic tonus
and respiration (Radaelli et al. 1994; Task Force of the
European Society of Cardiology and the North American
Society of Pacing and Electrophysiology, 1996; Furlan
et al. 2000). These mathematical results have been
addressed in several studies, which have suggested that
sympathetic activity is a critical determinant of blood
pressure fluctuations in a frequency range which is slower
than the rate of respiration (Japundzic et al. 1990; Cerutti
et al. 1991; Malliani et al. 1991).
Located in the hypothalamus, the paraventricular
nucleus (PVN) is a major sympathoexcitatory area that
becomes more active in conditions of hypertension,
such as in the spontaneously hypertensive rat (SHR)
model (Allen, 2002). Some authors have referred to this
region as a command nucleus providing feedforward
excitatory synaptic drives to co-ordinate lower brainstem
cardiovascular and respiratory motor activity (Dampney
et al. 2005). Activation of the PVN promotes an increase
in sympathetic output and a pressor effect mediated via
direct and indirect projections (via the rostral ventrolateral
medulla) to the spinal cord (Caverson et al. 1984; Shafton
et al. 1998; Pyner & Coote, 2000; Hardy, 2001).
Both electrical stimulation and chemical manipulation
of PVN neurons with bicuculline (a GABAA receptor
antagonist) or glutamate elevated sympathetic nerve
activity and caused hypertension in anaesthetized and
conscious rats (Kannan et al. 1989; Zhang et al. 2002).
In contrast, acute inhibition of the PVN with GABA or
muscimol reduces the blood pressure and sympathetic
nerve activity in SHRs (Allen, 2002). Lesions of the PVN
or transection of the brain caudal to the hypothalamus
promotes a decrease in blood pressure in SHRs but not
in Wistar–Kyoto (WKY) rats (Yamori & Okamoto, 1969;
Goto et al. 1981; Ciriello et al. 1984; Herzig et al. 1991;
Takeda et al. 1991).
Long-term manipulation of neurone excitability can
be performed by expressing a human inwardly rectifying
potassium channel (hKir2.1) under the control of a
selective neuronal promoter, such as synapsin (Duale et al.
2005, 2007). Inwardly rectifying potassium channels, such
as Kir2.1, are endogenously expressed in rat brain and have
recently been overexpressed as a means to reduce neuronal
membrane excitability (Yu et al. 2004; Duale et al. 2007;
Mizuno et al. 2007; Okada & Matsuda, 2008; Yoon et al.
2008; Howorth et al. 2009). Their long-term expression
can be achieved by the use of lentiviral vectors (LVVs)
derived from human immunodeficiency virus (Coleman
et al. 2003). Therefore, using a LVV to overexpress hKir2.1
channels within the PVN, we sought to determine the
long-term influence of this nucleus on the control of blood
pressure, heart rate, sympathetic activity and respiration in
SHRs, as well as homeostatic reflex control mechanisms.
Methods
All the experimental procedures were in accordance with
the European and Portuguese Law on animal welfare and
had the approval of the ethics committee of the Faculty
of Medicine, University of Lisbon, Portugal. Male Wistar–
Kyoto rats (n = 15) and SHRs (n = 15) were used, aged
12 weeks and weighing 363 ± 8 g. Animals, synchronized
to a 12 h–12 h light–dark cycle (light on at 07.00 h and
light off at 19.00 h), were housed individually and allowed
to freely move in standard plastic cages. Food and water
were available ad libitum.
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Viral vector construction and validation
Lentiviral vector construction was based on previous
studies (Waki et al. 2003; Duale et al. 2007). Briefly, LVV-
eGFP, used for the sham-treated group, was a mix of LV-
TREtight-GFP 5.7 × 109 IU and LV-Syn-Eff-G4BS-Syn-
Tetoff 6.2 × 109 IU in a ratio 1:4. This binary system
expresses enhanced green fluorescent protein (eGFP).
The LVV-hKir2.1 is a mix of LV-TREtight-Kir-cIRES-GFP
5.4 × 109 IU and LV-Syn-Eff-G4BS-Syn-Tetoff 6.2 × 109
IU in a ratio 1:4, which expresses eGFP and expresses
human inwardly rectifying potassium channels (hKir2.1)
in neurones. Validation of transduction efficacy and
transgene expression was assessed as described previously
by Duale et al. (2007) and included mRNA expression,
immunocytochemical and electrophysiological data.
Microinjection sites
Initially, we fine tuned our stereotaxic co-ordinates for
bilateral PVN microinjections in five SHRs and five
WKY rats anaesthetized with sodium pentobarbitone
(60 mg kg−1, I.P., Hikma Pharmaceuticals, London,
UK). Bilateral microinjections (0.05 μl) of LVV-eGFP
were performed. Using fluorescence microscopy and
histological reconstruction, we determined the correct co-
ordinates for PVN injections and the amount of LVV-eGFP
needed to limit transduction to the confines of the PVN.
Surgery
Spontaneoulsy hypertensive rats were divided into two
groups according to the microinjection content, i.e.
LVV-hKir2.1 (n = 8) and LVV-eGFP (n = 7). A control
group of WKY rats, with matching age, sex and
number of individuals, underwent the same surgical and
experimental protocol.
Implantation of telemetry probes. Rats were implanted
with radio-telemetry probes (DSI, St. Paul, Minnesota,
MN, USA) in the abdominal aorta under general
anaesthesia (sodium pentobarbitone, 60 mg kg−1, I.P.,
Hikma Pharmaceuticals). Animals were allowed to recover
for 15 days. Similar anaesthetic and surgical protocols were
applied to WKY rats (n = 15).
Bilateral microinjection in the PVN. Two weeks after
the probes were implanted, SHRs (n = 8) and
WKY rats (n = 8) under general anaesthesia (sodium
pentobarbitone, 60 mg kg−1, I.P., Hikma Pharmaceuticals)
were placed in a stereotactic frame (Kopf Instruments,
Tujunga, CA, USA), and a craniotomy was performed
using our previously determined co-ordinates for LVV-
hKir2.1 microinjections (0.05 μl) into the PVN (Bregma,
−1.6 mm; Lateral, ±1.41 mm; Deep, 7.4 mm; pipette
angle, 10 deg to bregma; Paxinos & Watson, 1986). Sham-
treated rats were microinjected in the same region with
LVV-eGFP (SHRs, n = 7; and WKY rats, n = 7). All
microinjections were performed bilaterally. Animals of
all groups were allowed to recover and monitored by
telemetry for 60 days. Heart rate (HR) and blood pressure
[BP; systolic (SBP), diastolic and mean] were recorded
continuously.
Metabolic evaluation
Rats were housed for 24 h in metabolic cages to evaluate
body weight, intake of food and fluid and production of
urine and faeces. Measurements were performed before
and 59 days after each microinjection.
Cardiorespiratory reflex evaluation
At 60 days, animals were anaesthetized (sodium
pentobarbitone, 60 mg kg−1, I.P., Hikma Pharm-
aceuticals). The trachea was cannulated below the
larynx to record tracheal pressure. The femoral and
carotid arteries and femoral vein were cannulated. Rectal
temperature was maintained at 38 ± 1◦C by a servo-
controlled heating blanket. The ECG was recorded with
the use of needle electrodes inserted into the limbs, and HR
was derived from the ECG. Baroreceptor and peripheral
chemoreceptor reflexes were activated twice, with an
interval of 5 min between stimuli. Baroreceptor reflex
was stimulated by phenylephrine (0.2 ml, 25 μg ml−1
I.V.; Sigma Aldrich). Peripheral chemoreceptor reflex
was stimulated with lobeline (0.2 ml, 25 μg ml−1, Sigma
Aldrich) injected retrogradely into the bifurcation of the
common carotid artery. Heart rate, BP (systolic, diastolic
and mean) and respiratory rate (RespR) were recorded
continuously thought the experiment.
Histology and immunochemistry
Animals were terminally anaesthetized and immediately
perfused transcardially with PBS (0.1 M; pH 7.4) followed
by 4% paraformaldehyde (0.1 M; pH 7.4). The brain was
removed and placed for 48 h in 15% (w/v) sucrose
solution. Coronal sections (18 μm thick) were cut on
a microtome and mounted on slides. The pipette tip
location and the microinjection diffusion in the PVN
were examined and documented. The microinjected
contents (LVV-hKir2.1 or LVV-eGFP) containing eGFP
allowed an estimation of virus dispersion. The eGFP-
labelled fluorescent regions were identified using an
epifluorescence microscope and plotted on standardized
sections from the atlas of Paxinos & Watson (1986).
Western blot analysis
The expression of hKir2.1 in the PVN was analysed
by Western blot 60 days after the microinjection of
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LVV-hKir2.1 (n = 8) or LVV-eGFP in SHRs (n = 7). The
PVN was dissected from both groups and homogenized by
sonication in ice-cold RIPA buffer (Sigma, St. Louis, MO,
USA) supplemented with a cocktail of protease inhibitors
(complete mini; Roche). Proteins were extracted from
the homogenates by centrifugation at 5000g for 10 min
at 4◦C, and protein concentration was determined with
a Bio-Rad DC Protein Assay kit. Proteins were resolved
by electrophoresis on a 10% Tris–glycine SDS-PAGE gel
and transferred to a polyvinylidene fluoride membrane
(Millipore, Bedford, MA, USA). Membranes were blocked
with 5% milk in Tween/Tris-buffered saline and incubated
overnight at 4◦C with rabbit anti-hKir2.1 polyclonal
antibody (Abcam, Cambridge, UK). After washing,
membranes were incubated for 1 h at room temperature
with HRP-conjugated goat anti-rabbit antibody (Bio-Rad,
Hercules, CA, USA), and immunoreactive proteins were
detected by Immobilon Western Chemiluminescent HRP
Substrate (Millipore, Bedford, MA, USA) and visualized
using Curix 60 (AGFA, Greenville, SC, USA). Membranes
were stripped with 0.1 M glycine (pH 2.2) and reprobed
with the α-tubulin antibody (Santa Cruz Biotechnology,
Dallas, TX, USA) for loading control.
Data acquisition and analysis
Telemetric data were acquired at 1 kHz and analysed with
suitable software (LabChart6, Powerlab; ADInstruments,
Oxford, UK). Mean values of HR, BP (systolic, diastolic
and mean) and RespR were extracted.
Baroreceptor and chemoreceptor reflex. The baro-
receptor reflex gain (BRG) was quantified by calculating
HR/BP (in beats per minute per millimetre of
mercury). Chemoreceptor (ChR) reflex was calculated
through the RespR derived from the tracheal pressure
before and after stimulation with lobeline, as follows:
ChR = RespRlobeline – RespRbasal. Blood pressure and HR
were also evaluated.
Analysis of BP and HR variability. Systolic BP and R–
R interval data were analysed (period of 3 min) in the
frequency domain (Fast Fourier Transform), using the
in-house software Fisiosinal (Tavares, 2011), to evaluate
sympathetic (LF band, 0.15–0.6 Hz of systolic BP) and
parasympathetic activity (HF band, 0.6–2.0 Hz of HR)
over time (Task Force of the European Society of
Cardiology and the North American Society of Pacing and
Electrophysiology, 1996; Marques-Neves et al. 2004).
Circadian light/dark heart rate and blood pressure profile.
Mean BP and HR values were calculated using the
continuous telemetric data and compared between light
(07.00–19.00 h) and dark phases (19.00–07.00 h).
Statistical analysis
Comparisons were performed between groups for the
same period and within the same group, before and after
the microinjections. For the statistical analysis, Student’s
paired t test and ANOVA for comparisons between groups
were used. All data were expressed as means ± SEM
and passed the normality test. Significance was taken as
P < 0.05.
Results
Effect of microinjection of LVV-hKir2.1 or LVV-eGFP on
24 h mean values of blood pressure, heart rate and
respiration
Basal BP values (recorded before microinjections) in
conscious SHRs (n = 15) were 158 ± 3 mmHg for systolic
BP, 135 ± 4 mmHg for diastolic BP and 142 ± 3 mmHg
for mean BP, and were significantly higher than the
values for WKY rats (119 ± 3, 91 ± 2 and 101 ± 1 mmHg,
respectively; n = 15; P < 0.0001). The SHRs showed a
higher baseline respiratory rate than WKY rats (77 ± 5
versus 61 ± 4 breaths min−1, respectively; P < 0.05) as
well as a lower HR (311 ± 5 and 367 ± 9 beats min−1;
P < 0.0001).
Thirty days after LVV-hKir2.1 microinjection, a
significant BP decrease (P < 0.05) was first observed,
but in order to evaluate its persistence, animals were
monitored for a further 30 days. On the 60th day after
lentiviral microinjection, values for SHRs for systolic,
diastolic and mean BP were 132 ± 6, 113 ± 5 and
120 ± 5 mmHg, respectively, corresponding to a decrease
in pressure of 26, 22 and 22 mmHg, respectively (P < 0.01;
Fig. 1). These BP changes were accompanied by a lowering
of HR (295 ± 3 beats min−1, P = 0.099) but RespR
remained unchanged. The decreased BP and HR values
approached those of normotensive animals. At the same
time, SHRs microinjected with LVV-eGFP were showing
increased values of systolic (174 ± 10 mmHg; P > 0.05),
diastolic (149 ± 11 mmHg; P > 0.05) and mean BP
(157 ± 10 mmHg; P > 0.05), together with a significantly
decreased HR (285 ± 6 beats min−1; P < 0.01). This
profile of BP and HR changes was expected and is a
consequence of maturation. In contrast, no significant
changes in BP, HR and RespR were observed in WKY rats
during the 60 day duration of the experimental protocol.
Effect of LVV-hKir2.1 microinjection on sympathetic
output measured indirectly
Spontaneously hypertensive rats showed putative evidence
for an overall decrease of cardiovascular autonomic
outflow at 60 days after LVV-hKir2.1 microinjection when
compared with basal autonomic output at day 0. In fact,
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by using fast Fourier transform applied to SBP and
R–R intervals, a decrease of LFSBP/HFRR ratio (from
0.07 ± 0.02 to 0.04 ± 0.01 mmHg2 ms−2; P > 0.05)
was observed, mainly due to a strong decrease in
sympathetic output expressed by LFSBP band power (from
0.79 ± 0.13 to 0.42 ± 0.09 mmHg2; P < 0.05). In SHRs,
the basal HFSBP (0.75 ± 0.10 mmHg2) was first reduced at
40 days and persisted until 60 days (0.33 ± 0.10 mmHg2;
P < 0.05) after LVV-hKir2.1, but it was unchanged in the
LVV-eGFP group (0.82 ± 0.38 mmHg2). Interestingly,
LF SBP was significantly reduced by 20 days after
LVV-hKir2.1 microinjection and occurred before the
fall in SBP. In contrast, at 60 days the LFSBP/HFRR
ratio for SHR LVV-eGFP was 0.08 ± 0.03 mmHg2
ms−2 and the LF was 0.86 ± 0.21 mmHg2 (P > 0.05).
The variations of mean LFSBP and LFSBP/HFRR, at
10 day intervals for each SHR group, are depicted in
Fig. 2. For WKY rats in basal conditions, the LFSBP
and LFSBP/HFRR ratio were 3.23 ± 0.36 mmHg2 and
0.43 ± 0.14 mmHg2 ms−2, respectively. No significant
changes in LF and LFSBP/HFRR ratio were observed
for WKY LVV-hKir2.1 (3.11 ± 0.44 mmHg2 and
0.40 ± 0.23 mmHg2 ms−2, respectively) and WKY LVV-
eGFP rats (2.56 ± 0.48 mmHg2 and 0.22 ± 0.08 mmHg2
ms−2, respectively).
Arterial baroreflex gain and peripheral chemoreflex
responsiveness
The injection of phenylephrine triggered, in all animal
groups, a progressive increase in mean BP, which was
accompanied by a progressive reduction in HR. In
SHRs, BRG increased significantly after LVV-hKir2.1
microinjection and approached the values of the normal
control rats. The SHR LVV-hKir2.1 group had a higher
BRG than the SHR LVV-eGFP group (0.51 ± 0.06
versus 0.33 ± 0.03 beats min−1 mmHg−1, respectively;
P < 0.05; Fig. 3). Interestingly, the BRG of WKY LVV-
hKir2.1 rats (1.29 ± 0.18 beats min−1 mmHg−1) was also
increased in comparison to the WKY LVV-eGFP group
(0.41 ± 0.02 beats min−1 mmHg−1; P < 0.0001), despite
all cardiovascular variables remaining unchanged.
Respiratory rate remained unchanged throughout
the full experimental protocol in all animal groups,
before and after the lentiviral microinjection. At
60 days after microinjection, the baseline values of
respiratory rate in the anaesthetized animals were
76 ± 3.4, 81 ± 4.9, 80 ± 4.5 and 67 ± 3.5 breaths min−1,
respectively, for SHR and WKY LVV-hKir2.1, SHR and
WKY LVV-eGFP. However, peripheral chemoreceptor
reflex activation with lobeline elicited a hyperventilatory
reflex response of different magnitude according to
the animal group. The SHR LVV-hKir2.1 animals
showed a decreased ventilatory response when compared
with the SHR LVV-eGFP group (24.4 ± 3.4 versus
38.1 ± 4.9 breaths min−1, respectively; P < 0.05; Fig. 3).
In contrast, there were no differences in the ventilatory
response between WKY LVV-hKir2.1 and WKY-eGFP
groups (23.3 ± 5.9 breaths min−1 for WKY LVV-hKir2.1
and 24.8 ± 4.2 breaths min−1 for WKY LVV-eGFP).
Mean BP responses to chemoreflex activation in SHR LVV-
hKir2.1 animals (from 140 ± 7 to 154 ± 9 mmHg) were
depressed compared with SHR LVV-eGFP rats (179 ± 9
to 193 ± 9 mmHg; P < 0.05), but HR responses were not
different (from 337 ± 23 to 359 ± 12 versus from 373 ± 10
to 362 ± 13 beats min−1, respectively). For the two WKY
groups, changes in BP and HR in response to peripheral
chemoreflex activation were not different.
Figure 1. Effect on systolic blood pressure, diastolic blood pressure and heart rate before (0 days) and
after microinjection of LVV-hKir2.1 (n = 7) or LVV-eGFP (n = 7)
∗P < 0.05, ∗∗P < 0.01, statistically significant differences between spontaneously hypertensive rat (SHR)
LVV-hKir2.1 and SHR LVV-eGFP groups. #P < 0.05, ##P < 0.01, statistically significant differences within
the group.
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Circadian variation of BP and HR and patterns of
nocturnal blood pressure profile
In basal conditions and without any intervention, the
pattern of circadian variation of BP and HR followed a
similar trend, with lower BP values during the light phase
relative to the dark phase. During the light phase, the
systolic, diastolic and mean BP of SHRs were significantly
higher than those for WKY rats (Table 1; P < 0.0001)
over the same time period. The same type of variation
was found for the dark phase, during which SHRs
showed higher values for BP parameters than WKY rats
(P < 0.0001; Table 1). Mean basal HR followed these
variations in BP inversely. The HR was significantly lower
during the light and dark phases for SHRs than for WKY
rats (P < 0.01; Table 1).
At 60 days after the LVV-hKir2.1 microinjection, SHRs
showed a significant decrease of systolic, diastolic and
mean BP during both the light and the dark phase
(both P < 0.01; Table 1). A significant decrease of HR
was observed during the light but not during the dark
phase (P > 0.05). For the SHR LVV-eGFP rats, HR,
diastolic, systolic and mean BP values for the light phase
and dark phase were increased as expected at 60 days
(Table 1). Finally, in WKY LVV-hKir2.1 as well as WKY
LVV-eGFP rats there was an increase in BP during the dark
phase without a distinct circadian rhythm. This profile was
maintained at 60 days after LVV-hKir2.1 and LVV-eGFP
PVN microinjections (Table 1).
Metabolic evaluation
A significant decrease in food intake was observed
in the SHR LVV-hKir2.1 group at 60 days after the
microinjection (Table 2). No other significant changes
were found in body weight, water intake, faeces and
urine production for all groups, before and after the
microinjections, suggesting that the physical inactivity
due to social isolation (only one animal per cage) could
have an impact on food consumption. Furthermore,
animals were not subjected to an adaptation period to the
metabolic cages, which could impact on our metabolic
data, constituting a study limitation.
Histological, immunohistochemical and Western blot
analysis
The microinjection sites were located within the PVN
according to the rat atlas of Paxinos & Watson (1986).
Enhanced green fluorescent protein was detected by
fluorescence microscopy as fluorescence confined to a
surface of 0.10–0.20 mm around the injection site. The
eGFP did not penetrate the third ventricular ependymal
lining. Through immunohistochemical studies, it
was confirmed that PVN neurones expressed eGFP
(Fig. 4).
The overexpression of hKir2.1 in the PVN was analysed
using Western blot. The PVN dissected from SHRs
microinjected with LVV-hKir2.1 showed an increased
expression of hKir2.1, on average about ninefold
increased when compared with the LVV-eGFP group
(Fig. 4).
Discussion
In the present study, we investigated the effect of
overexpressing an inwardly rectifying potassium channel
Figure 2. Mean (±SEM) low frequency (LF) and ratio of low (blood pressure) to high frequency (R–R
interval) [LF(BP)/HF(RR)] before (0 days) and at 10 day intervals after the microinjection of LVV-hKir2.1
or LVV-eGFP in SHRs
Note that the fall in LF systolic blood pressure (SBP) occurred a week before the fall in SBP, suggesting a
causative association. ∗P < 0.05, statistically significant difference between groups.
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in the PVN to lower neuronal activity, while measuring
BP chronically, as well as its reflex control, in a rat model
of hypertension. Our study is the first to demonstrate
that chronic suppression of PVN neuronal activity in
freely moving SHRs causes a sustained reduction in
arterial blood pressure (>60 days) together with a decrease
of sympathetic activity, a downregulation of peripheral
chemoreflex responsiveness and an improvement of
baroreflex gain. No such changes were found in the control
groups of both rat strains that underwent comparable
experimental protocols.
The PVN of the hypothalamus is well known for
its importance in autonomic control and, in particular,
for cardiovascular regulation. Several anatomical and
electrophysiological studies have shown that PVN
neurones project either directly to the spinal cord
or to the rostral ventrolateral medulla (Coote, 2007),
thereby accessing sympathetic neurones to modulate
blood pressure (Hosoya et al. 1991; Loewy, 1991; Coote,
1995, 2005; Ranson et al. 1998; Motawei et al. 1999;
Pyner & Coote, 1999, 2000; Badoer, 2001). As an example,
electrolytic lesions of the PVN in SHRs elicited an acute
reduction of sympathetic activity together with a decrease
of blood pressure (Takeda et al. 1991). Other acute
studies, performed under general anaesthesia, showed that
muscimol injections into the PVN lowered BP and renal
sympathetic nerve activity in both SHRs and WKY rats,
indicating that this region was tonically active in both
animal strains to control BP and peripheral sympathetic
activity (Allen, 2002). In the SHR, sympathetic activity
is known to be overactivated even before hypertension
develops (Simms et al. 2009). Several studies have
pointed out that the persistent increase in sympathetic
tone is a major contributor to both the initiation
and the maintenance of the hypertensive condition
(Yamada et al. 1988; Grassi, 2004b; Smith et al. 2004;
Guyenet, 2006; Fisher & Paton, 2012). In fact, increased
sympathetic activity has been detected in normotensive
individuals with a family history of hypertension and
in individuals with essential hypertension, but not
in those with secondary hypertension (Yamada et al.
1988; Grassi et al. 1998; Grassi, 2004a, 2009). Likewise,
high plasmatic noradrenaline levels have also been
associated with essential hypertension, being consistently
increased in younger hypertensive patients (Grassi, 1998),
and increased peripheral sympathetic nervous activity
has been detected by microneurographic techniques in
hypertensive patients (Anderson et al. 1989; Grassi,
1998; Greenwood et al. 1999; Mano, 2012). Several
studies, both in human subjects and in animal models,
have demonstrated an association between the circadian
variation of BP values, the hypertensive condition, the
sympathetic activation, the end-organ damage and the
worsening of cardiovascular outcome (White, 2000;
Pickering & Kario, 2001; Weber, 2002). Thus, the idea of a
long-term modulation of the level of sympathetic activity,
at its central origin, as a way to control and treat high blood
pressure and to increase cardiovascular compliance, is very
appealing. In particular, the manipulation of sympathetic
cell excitability by modulation of K+ channel expression,
to hyperpolarize neuronal resting membrane potential, is
an attractive hypothetical therapeutic strategy (Duale et al.
2007).
In the present work, our purpose was to depress
the activity of PVN neurones chronically by the
overexpression of K+ channels exclusively in PVN
Figure 3. Effect of bilateral microinjections of LVV-hKir2.1 or LVV-eGFP into the paraventricular nucleus
on baroreflex gain (A) and chemoreflex variation (B), 60 days after microinjection
In the SHR LVV-hKir2.1 group, there is an increase in the baroreflex gain and a decrease in the
chemoreflex ventilatory response. ∗P < 0.05, statistically significant differences between groups.
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Table 1. Blood pressure (in millimetres of mercury) and heart rate (in beats per minute) during the light and dark phases for all
groups before and 59 days after the microinjection
Light phase Dark phase
Group SBP DBP MBP HR SBP DBP MBP HR
Basal
SHR 156 ± 3 132 ± 3 140 ± 3 297 ± 6 160 ± 4 137 ± 4 145 ± 4 325 ± 6
WKY 118 ± 3 90 ± 2 100 ± 1 362 ± 9 120 ± 3 92 ± 2 102 ± 2 373 ± 11
59 days after microinjection
SHR LVV-hKir2.1 131 ± 5∗ 113 ± 4∗ 119 ± 4∗ 271 ± 2 133 ± 7∗ 114 ± 6∗ 120 ± 6∗ 320 ± 5∗
SHR LVV-eGFP 172 ± 11 145 ± 11 154 ± 10 264 ± 5 177 ± 10 152 ± 11 160 ± 10 305 ± 7
WKY LVV-hKir2.1 117 ± 4 87 ± 3 97 ± 2 340 ± 10 121 ± 2 91 ± 4 101 ± 3 378 ± 12
WKY LVV-eGFP 114 ± 2 88 ± 3 96 ± 2 354 ± 5 116 ± 2 92 ± 3 100 ± 2 389 ± 2
Values are expressed as means ± SEM. Abbreviations: DBP, diastolic blood pressure; HR, heart rate; MBP, mean blood pressure;
and SBP, systolic blood pressure; SHR LVV-hKir2.1, Spontaneously hypertensive rats microinjected with LVV-hKir2.1; SHR LVV-eGFP,
Spontaneously hypertensive rats microinjected with LVV-eGFP; WKY LVV-hKir2.1, Wistar Kyoto rats microinjected with LVV-hKir2.1;
WKY LVV-eGFP, Wistar Kyoto rats microinjected with LVV-eGFP. ∗P < 0.01, statistically significant difference between basal and day
59 values.
Table 2. Metabolic evaluation of spontaneously hypertensive rats before injection and 59 days afterwards
Group Weight (g) Food (g) Water (ml) Faeces (g) Urine (ml)
Before microinjection; basal conditions
SHR LVV-eGFP −1 ± 2.0 19 ± 3.5 27 ± 2.2 9 ± 2.1 11 ± 1
SHR LVV-hkir2.1 −1 ± 1.4 24 ± 1.3 40 ± 4.2 14 ± 3.1 16 ± 3.5
After microinjection (at 59 days)
SHR LVV-eGFP −3 ± 1.3 27 ± 1.6 31 ± 4.0 13 ± 1.5 12 ± 0.9
SHR LVV-hkir2.1 −1 ± 0.6 20 ± 0.6∗ 32 ± 4.9 8 ± 0.9 16 ± 2.1
Values are expressed as means ± SEM. Abbreviations: SHR LVV-hKir2.1, Spontaneously hypertensive rats microinjected with
LVV-hKir2.1; SHR LVV-eGFP, Spontaneously hypertensive rats microinjected with LVV-eGFP; WKY LVV-hKir2.1, Wistar Kyoto rats
microinjected with LVV-hKir2.1; WKY LVV-eGFP, Wistar Kyoto rats microinjected with LVV-eGFP. ∗P < 0.05, statistically significant
difference between basal and day 59 values.
Figure 4. Lentiviral vector-mediated transduction of enhanced green fluorescent protein (eGFP) in the
paraventricular nucleus
Confocal microscope images of eGFP-expressing cells in the paraventricular nucleus following injection
of lentiviral vector into this site. Scale bar in A represents 20 μm and scale bar in B represents 10 μm.
C, Western blot analysis of sham-treated SHRs (lanes 1 and 2) and LVV-hKir2.1 microinjected SHRs (lanes
3 and 4). Results show an overexpression of hKir2.1 in LVV-hKir2.1-microinjected SHRs. α-Tubulin was
used as the housekeeping gene.
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neurones, in order to evaluate its consequences upon
long-term blood pressure regulation in an animal model
of hypertension. We overexpressed a human inwardly
rectifying potassium channel (hKir2.1) under the control
of a synapsin promoter that was neurone specific
(Duale et al. 2005a; Duale et al. 2005b). Lentivirus
was used because its expression has been shown to
be sustained within PVN neurones in the long term
(Coleman et al. 2003). In previous studies, Duale et al.
(2007) and Howorth et al. (2009) showed that hKir2.1
overexpression hyperpolarized the membrane potential
of cultured cathecolaminergic PC12 cells by ∼10 mV,
which is expected to result in ‘electrical silencing’ of
PVN neurones (Duale et al. 2007; Howorth et al. 2009).
Similar overexpression strategies have been used to reveal
that electrical silencing of neurones affected development
in ovo (Yoon et al. 2008), neuronal activity in vivo
(Okada & Matsuda, 2008) and the ability of neurones
to make and maintain connections in vivo (Yu et al.
2004; Mizuno et al. 2007; Hendy, 2010). This virus-
mediated approach has the advantage of being site specific
and enabling overexpression in adulthood, which avoids
the development of putative compensatory mechanisms
associated with transgenic animals (Hendy, 2010).
Our results show that LVV-hKir2.1 treatment of the
PVN in SHRs lowered SBP by ∼15% (>20 mmHg).
This decline of SBP, which was accompanied by a
decrease in HR, was statistically confirmed at 30 days
after the lentiviral microinjection and persisted until the
animals were killed 60 days postinjection. Interestingly,
the LF spectra of SBP (indicative of sympathoinhibition)
occurred before the fall in SBP (i.e. 20 versus 30 days),
suggesting a putative association between the changes
in both variables. Furthermore, the fall in HF SBP
is indicative of reduced respiratory modulation of
arterial pressure and could include reduced respiratory–
sympathetic coupling, a phenomenon known to raise total
peripheral resistance in the SHR (Simms et al. 2009). In
contrast, changes in diastolic BP were significant only
after 50 days, suggesting the involvement of an additional
mechanism. This reveals novel insight into the long-term
control of arterial pressure in hypertension by the PVN.
It also indicates that the system does not adapt. This
could be explained by the associated improvement of
baroreflex gain and/or a downregulation of peripheral
chemoreflex responsiveness to stabilize lower levels of
blood pressure, as we observed. We propose that these
changes were a result of reduced electrical excitability of
PVN premotor sympathetic neurones, but we cannot rule
out reduced release of vasopressin and oxytocin. This is
consistent with our neuroanatomical Western blot analysis
confirming that hKir2.1 protein overexpression was within
the PVN region. Interestingly, respiratory rate remained
unchanged in all experimental groups, suggesting that
there is no tonic excitatory drive from the PVN affecting
this variable in hypertensive or normotensive rats.
Additionally, we saw no tonic influence from the PVN
on the resting arterial pressure level in normotensive rats,
which contrasts with a previous acute in vivo study (Allen,
2002).
It is well accepted that neurogenic hypertension is
accompanied by an impairment of the baroreceptor reflex
(Grassi et al. 1998). Our data showed that depressing PVN
neuronal activity improved baroreflex gain. Previous work
from several authors has shown that during the course
of an alerting reaction there is a decrease in baroreflex
efficacy and a facilitation of the carotid chemoreceptor
reflex due to modifications of synaptic integration at the
level of the nucleus tractus solitarii; this might include
mechanisms involving GABA and angiotensin II release
within the nucleus tractus solitarii (Jordan et al. 1988;
Spyer K, 1990; Silva-Carvalho et al. 1995a,b; Kasparov et al.
1998; Kasparov & Paton, 1999; Head & Mayorov, 2001;
Rocha et al. 2003). Such an angiotensinogenic mechanism
seems to be particularly active in pathophysiological
conditions such as myocardial ischaemia and hypertension
(Rocha et al. 2003; Rosário et al. 2003; Maximino et al.
2006), and its behaviour can be modulated by intervening
pharmacologically on AT1 receptors within the nucleus
tractus solitarii (Kasparov et al. 1998; Kasparov & Paton,
1999; Rocha et al. 2003; Rosário et al. 2003). In fact,
during myocardial ischaemia, AT1 blockade reversed the
remodelling of baroreceptor and chemoreceptor reflex
function in a way similar to that elicited upon the
overexpression of hKir2.1 in PVN neuronal cells (Rocha
et al. 2003; Rosário et al. 2003).
The demonstration of a non-dipper blood pressure
profile in animal models remains difficult, mainly due to
the failure to establish a clear distinction between day and
night values. This was confirmed in our study, because
through PVN-induced sympathetic manipulations, we
were only able to modify BP light–dark values of SHRs
which approached those of WKY rats. However, we were
unable to modify the day and night profile of BP value
variations in both strains. This inability to define a light–
dark profile in rats similar to the one set for human
subjects may be due to the intermittent behaviour rats,
with alternating awake and sleep periods in both the light
and the dark phase. It is likely that the only way to define
the light and dark phase profiles of rats better would be by
monitoring of cerebral activity through EEG, which was
outside the scope of the present work.
In conclusion, the present work shows that the
intervention on central sympathoexcitatory neurone
excitability through the genetic manipulation of
expression of K+ channels is able to alter peripheral
blood pressure in the long term. This occurs by
remodelling of the sympathetic outflow and restores
the imbalance of peripheral reflex mechanisms that
maintain cardiovascular homeostasis. Our data, from an
C© 2013 The Authors. Experimental Physiology C© 2013 The Physiological Society
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animal model, give insights into the pathophysiological
mechanisms involved in the aetiology of neurogenic
hypertension and provide novel hypothetical therapeutic
interventions at both the central and the peripheral
level of the autonomic nervous system to control
sympatoexcitation.
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